Vuno

What Vuno does

VUNO Inc. is a Seoul-based, KOSDAQ-listed medical AI company founded in 2014 that develops deep learning-based software for diagnostic decision support and clinical monitoring. The company's core platform analyzes medical imaging (chest X-ray, fundus, CT, MRI), digital pathology slides, biosignals (ECG, vital signs), and speech to deliver AI medical devices marketed under the VUNO Med brand and a consumer health platform under the VUNO Care brand.

The product portfolio comprises four primary offerings: VUNO Med-Chest X-ray (abnormality detection in chest radiographs), VUNO Med-Fundus AI (12-class fundus finding classification), VUNO Med-DeepCARS (24-hour cardiac arrest risk prediction from vital signs, FDA-approved with a validated 21% reduction in cardiac arrest in a secondary hospital study), and VUNO Care-HATIV, a chronic disease management platform that extends clinical monitoring into the consumer health domain via VUNO Mall and Naver Smart Store. VUNO holds FDA approvals for multiple AI medical devices and Korea MFDS clearances, supported by ISO/IEC 27001:2022 and ISO/IEC 27701:2019 certifications.

VUNO monetizes through B2B sales of medical AI software to hospitals and healthcare systems (quote-based annual licensing), B2C subscriptions and unit sales via its consumer health e-commerce storefronts, and international licensing/partnership revenue. Distribution combines direct enterprise sales in Korea with channel partnerships in Europe (Contextflow in Austria, Mesalvo in Germany targeting 900+ hospitals) and a US subsidiary (VUNO Med Inc.) for the American market. Reported Q1 2026 revenue was 61억 won (6.1 billion KRW), with cumulative disclosed funding of approximately $37M across multiple rounds between 2014 and 2026.

Name

Vuno

Legal name

주식회사 뷰노

Website

https://vuno.co

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

51–100 employees

Short description

VUNO is a Seoul-based medical AI company that develops FDA-approved deep learning software for radiology (chest X-ray, fundus), cardiac arrest prediction (DeepCARS), and consumer chronic disease management (HATIV), selling to hospitals and healthcare systems globally.

Ownership category

akta.pro rank

Product category

Medical AI Software

NAICS

Software Publishers (5132), Custom Computer Programming Services (541511), Scientific Research and Development Services (5417)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

akta.pro secondary industries

Medical Imaging AI (HDAAAEAH), Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD), SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), Healthcare & Wellness Personalization (HDAAAGAI)

Keywords

• Medical AI software
• Diagnostic imaging AI
• Cardiac arrest prediction
• Digital pathology AI
• Chronic disease platform

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. VUNO Med (Medical Device AI Software): Sale of FDA-approved and Korea MFDS-cleared AI medical devices (Chest X-ray, Fundus AI, DeepCARS) to hospitals and healthcare systems. Revenue generated from device licensing, software subscriptions, and potentially one-time device sales.
2. VUNO Care - HATIV (Consumer Health Platform): Chronic disease management platform sold directly to consumers via e-commerce (VUNO Mall, Naver Smart Store). Subscription or unit-based pricing for personal health monitoring devices and services.
3. International Licensing and Partnership Revenue: Revenue from international market expansion through licensing agreements, partnerships with European distributors (Contextflow, Mesalvo), and potential royalty arrangements as DeepCARS and other solutions enter new geographies.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

VUNO develops and sells deep learning-based medical AI software products under two brands: VUNO Med (B2B medical device AI for hospitals including Chest X-ray analysis, Fundus AI, and DeepCARS cardiac arrest prediction) and VUNO Care (B2C consumer health platform HATIV for chronic disease management). The company generates revenue through software/device licensing and subscriptions to clinical and consumer health monitoring solutions that analyze medical imaging, biosignals, and digital pathology data.

Product overview

Vuno offers a unified medical AI platform with two main product lines: VUNO Med and VUNO Care. VUNO Med comprises diagnostic AI solutions including Chest X-ray (AI-powered chest X-ray analysis), Fundus AI (fundus image analysis), and DeepCARS (cardiac arrest prediction using vital signs/ECG). VUNO Care includes HATIV, a chronic disease management platform extending clinical healthcare services to personal health monitoring. The platform analyzes diverse medical data including medical imaging (CT/X-ray/MRI), pathology slides, biosignals (ECG/vital signs), and supports speech processing. Vuno Med products are FDA-approved and deployed in hospitals, while the company is expanding globally into US and European markets.

Differentiator

Problem solved

Functional benefit

Brands

• VUNO Med: Medical AI solutions brand including Chest X-ray, Fundus AI, and DeepCARS products for healthcare professionals
• VUNO Care
• VUNO Med-Chest X-ray
• VUNO Med-Fundus AI
• VUNO Med-DeepCARS
• VUNO Care-HATIV
• DeepCARS
• HATIV

Products and services

• VUNO Med-Chest X-ray AI medical device software that accurately identifies the presence of major abnormal findings in chest X-ray images and pinpoints the suspected location of abnormalities. Sold to hospitals, radiology departments, and healthcare institutions as an FDA-approved and Korea MFDS-cleared AI medical device for clinical decision support.
• VUNO Med-Fundus AI AI medical device software that classifies normal versus abnormal fundus images and detects the presence or absence of 12 common fundus findings. Sold to hospitals, ophthalmology clinics, and healthcare institutions for retinal screening and diagnostic decision support.
• VUNO Med-DeepCARS FDA-approved AI medical device that predicts the risk of cardiac arrest within 24 hours based on patient vital signs including ECG data. Validated in a secondary hospital study demonstrating a 21% reduction in cardiac arrest occurrences. Sold to hospitals and healthcare systems as an Early Warning System for clinical decision support.
• VUNO Care-HATIV Chronic disease total platform service that extends VUNO's medical AI capabilities from the clinical domain into personal health management, integrating ECG measurement, vital sign monitoring (heart rate, blood pressure, blood glucose, body temperature), and symptom tracking for chronic disease patients. Sold directly to individual consumers via VUNO Mall and Naver Smart Store as a subscription or unit-priced personal health device/service.

Quantifiable outcome

• 21% reduction in cardiac arrest occurrences validated in secondary hospital study
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Partnerships

Three partnerships are on record, tiered core.

• Korean Society of Tuberculosis and Respiratory DiseasescoreStrategic or Co-development Partner · 2 February 2026VUNO signed an MOU with the Korean Society of Tuberculosis and Respiratory Diseases to strengthen clinical evidence for medical AI. The partnership aims to advance clinical validation and scientific evidence for VUNO's AI diagnostic solutions, particularly VUNO Med-Chest X-ray for tuberculosis and respiratory disease detection.
• Contextflow (Austria)coreStrategic or Co-development Partner · 28 October 2025VUNO Inc. signed a strategic MOU with Austrian imaging AI company Contextflow to expand the use of VUNO Med-DeepCARS (AI-based cardiac arrest prediction solution) in Europe. The collaboration involves technical integration, clinical validation, and joint go-to-market activities targeting European hospital markets. Contextflow contributes imaging AI expertise and local market access in Austria and broader Europe.
• Mesalvo (Germany)coreStrategic or Co-development Partner · 28 October 2025VUNO Inc. signed a strategic MOU with German hospital information system provider Mesalvo to expand DeepCARS in Europe. Mesalvo contributes hospital IT system integration capabilities and reimbursement strategy expertise. The partnership aims to reach over 900 hospitals across Europe through technical integration, validation, and reimbursement strategy collaboration.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Aidoc: Israel-based medical imaging AI company offering AI worklist triage and diagnostic support across CT, X-ray, and MRI — directly comparable to VUNO Med's imaging portfolio for hospital radiology departments.
• Lunit: South Korean medical AI company and the most direct competitor to VUNO, especially in AI chest X-ray (Lunit INSIGHT CXR) and oncology imaging. Closely comparable product set, geography, regulatory profile, and customer base.
• Oxipit: Lithuania-based AI company developing chest X-ray and orthopedic imaging AI products, including autonomous reporting — directly comparable to VUNO Med's X-ray AI offering.
• RapidAI: US-based medical imaging AI company focused on neurovascular and vascular imaging AI — comparable to VUNO in clinical decision-support imaging AI sold to hospital systems, though in a different clinical vertical.
• Annalise.ai: Australia-based AI company offering comprehensive chest X-ray abnormality detection (200+ findings) — direct competitor to VUNO Med-Chest X-ray in the AI triage market.
• Qure.ai: India-headquartered medical imaging AI company competing with VUNO Med-Chest X-ray and VUNO Med-Fundus AI. Direct competitor in chest X-ray triage and head CT/trauma AI, sold globally to hospitals.

Regional players

• Deep Bio: South Korean AI company focused on digital pathology AI for prostate cancer — comparable peer to VUNO in Korean medical AI ecosystem and overlapping digital pathology capability.
• JLK Inspection: South Korean AI healthcare company developing stroke and brain imaging AI — a regional peer to VUNO in the Korean medical AI market and one of the named local players in the same Korea AI healthcare category.

Broad incumbents

• Nanox (Zebra Medical Vision): Global medical imaging company that acquired Zebra Medical Vision — offers AI-driven imaging analytics platform comparable to VUNO Med's imaging portfolio across a broader clinical and hardware-integrated footprint.

Emerging players

• Contextflow: Austrian imaging AI company partnered with VUNO for DeepCARS distribution. Overlaps with VUNO's radiology AI capabilities (CT lung and 3D imaging) and is a meaningful adjacent peer in the EU hospital AI market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCFdkmVMJLxIMx1N9CbD0oLQ
• Facebookfacebook.com/vunoinc
• LinkedInlinkedin.com/company/vuno-inc
• Xx.com/vunoinc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds8 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vuno